Background: Mycosis fungoides (MF) is the most common skin lymphoma. The aetiology of MF remains unknown, and no therapy has to date significantly altered patient survival. Objective: The present study examines trends in survival of MF patients in a well-defined population-based disease group, namely patients registered over a 40-year period at the Thames Cancer Registry, Southeast England. Methods: The Thames Cancer Registry is a population-based registry, covering a population of approximately 14 million people. Data were taken from the Surveillance, Epidemiology and End Results cancer registry programme and the National Centre for Health Statistics. The database was used to identify cases of MF diagnosed between 1961 and 2000. A total of 985 records were identified, 821 (83%) of which had complete information on age, sex, year of diagnosis and area of residence. The observed and relative survivals of patients diagnosed during the periods 1971–1975, 1981–1985 and 1991–1995 were examined over a 5-year period of follow-up, using the relsurv Stata program to perform Cox proportional hazard analysis. Results: A total of 821 MF eligible patients were available with a median follow-up of 4.3 years and a maximum follow-up of 30 years. The overall 5-year relative survival rate was 80%, and there was marked improvement between 1971 and 1981. The prognostic factors leading to a significantly poorer survival were high age, male sex, the presence of the Sézary syndrome, the use of hormone treatment and radiotherapy. Conclusions: A statistically significantly better survival over the last 20 years was found. The prognosis is generally good for most patients but not all. The best survival was seen for the female patients under 45 years of age without the presence of the Sézary syndrome. This difference in survival may be partly due to a difference in the disease stage or different treatment, or to both.

Keywords:
Population-based survival, Mycosis fungoides, Prognostic factors, Thames cancer registry, Southeast England
1.
Weinstock MA, Horm JW: Mycosis fungoides in the United States. JAMA 1988;60:42–46.
2.
Cohen SR, Stenn KS, Braverman IM, Beck GJ: Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor. Cancer 1980;46:2654–2666.
3.
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds): Cancer Incidence in Five Continents. IARC Scientific Publication No 143. Lyon, International Agency for Research on Cancer, 1997, vol VII.
4.
Bernstein L, Deapen D, Ross RK: Mycosis fungoides. JAMA 1989;261:1882.
5.
Linet MS, McLaughlin JK, Fraumeni JF, et al: Mycosis fungoides and occupation in Sweden. J Natl Cancer Inst 1989;81:1842–1843.
6.
Epstein EH, Levin DL, Croft LD, Lutzner MA: Mycosis fungoides: Survival, prognostic features, response to therapy and autopsy finding. Medicine 1972;15:61–72.
7.
Fuks ZY, Bagshaw MA, Farber EM: Prognostic signs and the management of mycosis fungoides. Cancer 1973;32:1385–1395.
8.
Hoppe RT, Fuks ZY, Bagshaw MA: The rationale for curative radiotherapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 1977;2:843–851.
9.
Kelin R, Burges GH, Helm F: Neoplasms of the skin; in Holland JF, Frie E III (eds): Cancer Medicine, ed 1. Philadelphia, Lippincott, 1975, pp 696–703.
10.
Van Scott EJ, Kalmason JD: Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard. Cancer 1973;32:18–30.
11.
Vonderheid EC, Van Scott EJ, Johnson WC, Grekin DA, Asbell SO: Topical chemotherapy and immunotherapy of mycosis fungoides. Arch Dermatol 1977;113:454–462.
12.
Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998;16:2780.
13.
Jaffe ES, Harris NL, Chan JKC, Stein H, Vardiman J: Proposed World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissues. Am J Surg Pathol 1997;21:114.
14.
Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK: World Health Organization Classification of lymphomas: A work in progress. Ann Oncol 1998;9:S25.
15.
Wilson LD, Jones GW, Kacinski BM, Edelson RL, Health PW: Cutaneous T-cell lymphoma; in Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 6. Philadelphia, Lippincott Williams & Wilkins, 2001.
16.
Dewey WC, Ling CC, Meyn RE: Radiation-induced apoptosis: Relevance to radiotherapy. Int J Radiat Oncol Biol Phys 1995;33:781–782.
17.
Quiros PA, Kacinski BM, Wilson LD: Extent of skin involvement as a prognostic indicator of disease free and overall survival in T3 stage cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. Cancer 1996;77:1912–1924.
18.
Wilson LD, Kacinski BM, Jones GW: Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 1998;40:109–112.
19.
Micaily B, Campbell O, Moser C, Vonderheid EC, Brady LW: Total skin electron beam and total nodal irradiation of cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 1991;20:809–814.
20.
Micaily B, Vonderheid EC, Brady LW, Andrews C: Total skin electron beam and total nodal irradiation for treatment of patients with cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 1985;11:1111–1115.
21.
Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Cancer 1999;85:1985–1990.
22.
Rijlaarsdom U, Scheffer E: Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991;2:216–220.
23.
Kuzel TM, Roenigk HH Jr, Rosen ST: Mycosis fungoides and the Sézary syndrome: A review of pathogenesis, diagnosis, and therapy. J Clin Oncol 1991;9:1298–1313.
24.
Tan RA, Butterworth CM, McLaughlin H, Malka S, Samman PD: Mycosis fungoides, a disease of antigen persistence. Br J Dermatol 1974;91:607–616.
25.
King Ismael D, Bernard Ackerman A: Guttate parapsoriasis/digitate dermatosis (small plaque parapsoriasis) is mycosis fungoides. Am J Dermatopathol 1992;14:518–530.
26.
Esteve J, Benhamou E, Raymond L: Descriptive Epidemiology. IARC Scientific Publication No 128 (Statistical Methods in Cancer Research). Lyon, International Agency for Research on Cancer, 1994, vol IV, pp 231–236.
27.
Cox DR: Regression models and life-tables. J R Stat Soc 1972;B34:187–220.
28.
Hoppe RT, Wood GS, Abel EA: Mycosis fungoides and the Sézary syndrome: Pathology, staging and treatment. Curr Probl Cancer 1990;14:293–371.
29.
Weinstock MA, Reynes JF: The changing survival of patients with mycosis fungoides. Cancer 1999;85:208–212.
30.
Kim YH, Bishop K, Varghese A, Hoppe RT: Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995;131:1003–1008.
31.
Swanbeck G, Roupe G, Sandströn MH: Indications of a considerable decrease in the death rate in mycosis fungoides by PUVA treatment. Acta Derm Venereol 1994;74:465–466.
32.
Levi JA, Wiernick PH: Management of mycosis fungoides: Current status and future prospect. Medicine 1975;54:63.
33.
Weinstock MA, Gardstein B: Twenty-year trends in the report incidence of mycosis fungoides and associated mortality. Am J Publ Health 1999;89:1240–1244.
34.
Swanbeck G, Roupe G, Sandströn MH: Indication of a considerable decrease in the death rate in mycosis fungoides by PUVA treatment. Acta Derm Venereol 1994;74:465–466.
35.
Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R: Transformation of mycosis fungoides/Sézary syndrome: Clinical characteristics and prognosis. Blood 1998;92:1150–1158.
36.
Morales MM, Putcha V, Bell CMJ, Møller H, Linklater K, Olsen J, Llopis A: An age, period and cohort model of the incidence of mycosis fungoides in South East England. In press.
37.
Wolfe JD, Trevor ED, Kjeldsberg CR: Pulmonary manifestations of mycosis fungoides. Cancer 1980;46:2648–2653.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.